Skip to main content

obesity drugs

3 articles found

NVO: GLP-1 Giant Falls to 10x Earnings on Lilly Fears

Novo Nordisk shares have collapsed to $37.45, a 59% decline from their 52-week high of $91.90, after the company's next-generation obesity drug CagriSema delivered clinical trial results that trailed Eli Lilly's Zepbound. The February 27 selloff alone erased 21% of the stock's value in a single session, marking the most dramatic repudiation of a GLP-1 leader since the obesity drug revolution began. At 10.3 times trailing earnings, Novo Nordisk now trades at a valuation that would be cheap for a utility company — let alone a pharmaceutical giant that generated DKK 308 billion ($44 billion) in revenue last year with 81% gross margins. The market cap has contracted to $166.5 billion, roughly half of where it stood six months ago. The question facing investors is whether the CagriSema disappointment is a fundamental thesis-breaker or whether the market has overreacted. Novo Nordisk still dominates the GLP-1 market alongside Eli Lilly, with Wegovy and Ozempic generating massive cash flows. But with the company guiding for a 5–13% decline in 2026 sales due to U.S. price compression, the near-term outlook is genuinely challenging. For context on how NVO reached this point, see our [earlier analysis of the 50% price reduction](/articles/nvo-analysis-novo-nordisks-50-price-slash-creates-a-deep-value-puzzle-for-glp-1-investors) that preceded this latest crash.

NVONovo NordiskGLP-1

NVO: Novo Nordisk's 50% Price Slash Creates a Deep-Value

Novo Nordisk (NVO) has gone from the world's most valuable healthcare company to a deep-value opportunity in the span of twelve months. Shares closed at $38.16 on February 25, 2026 — down 59% from their 52-week high of $93.80 and trading at just 10.5x trailing earnings. The Danish pharmaceutical giant hit a fresh 52-week low of $37.65 during today's session on volume 2.6 times the daily average, as investors digested the company's announcement that it will cut U.S. list prices on Ozempic and Wegovy by up to 50% starting in 2027. The price cuts represent a strategic pivot that could reshape the entire GLP-1 market. For years, Novo Nordisk and rival Eli Lilly have commanded premium pricing for their obesity and diabetes drugs — Ozempic and Wegovy carry U.S. list prices above $1,000 per month. By voluntarily halving prices, Novo is betting that volume gains from dramatically expanded insurance coverage and patient access will more than offset the per-unit revenue decline. It is a gamble that pits near-term margin compression against long-term market dominance. For investors, the question is straightforward: does a sub-11x P/E ratio adequately compensate for the margin headwinds ahead, or is the selloff a classic overreaction that creates a generational entry point into the world's dominant GLP-1 franchise? The answer lies in Novo's financial fundamentals, its competitive moat, and whether the company's massive manufacturing investments can deliver the scale needed to make lower prices profitable.

NVONovo NordiskOzempic

Novo Nordisk Slashes Ozempic and Wegovy Prices by 50%

Novo Nordisk dropped a bombshell on the pharmaceutical industry this week, announcing plans to cut the U.S. list prices of its blockbuster GLP-1 drugs — Wegovy, Ozempic, and Rybelsus — by up to 50% starting January 1, 2027. The new uniform list price of $675 per month, down from current prices ranging between $1,027 and $1,350, marks the most aggressive pricing move yet in the rapidly evolving obesity and diabetes drug market. The announcement sent Novo Nordisk shares tumbling to a fresh 52-week low of $37.65, extending a brutal decline that has erased roughly 75% of the stock's value since its mid-2024 peak. The price cuts arrive at a moment of acute vulnerability for the Danish drugmaker. Just days earlier, Novo reported disappointing results from its REDEFINE 4 trial pitting next-generation drug CagriSema against Eli Lilly's tirzepatide (Zepbound), sending shares down over 16% in a single session. With its market capitalization now sitting at roughly $169 billion — down from north of $600 billion at its zenith — Novo Nordisk is attempting a high-stakes pivot: sacrificing near-term pricing power to defend market share against an increasingly dominant Eli Lilly and a swarm of pharma giants preparing to enter the weight-loss arena. The implications extend far beyond one company's balance sheet. Novo's decision reshapes the economics of a drug category projected to exceed $150 billion in annual sales by the end of the decade, puts immediate pressure on Eli Lilly to respond, and could dramatically expand the patient population with affordable access to GLP-1 therapies. For investors, the question is whether this is a desperate retreat or a calculated long-term play.

Novo NordiskGLP-1 drugsOzempic price cut